Tobacco use disorder pharmacotherapy widens past nicotine replacement and varenicline
Cytisine availability, novel nicotine receptor pharmacotherapy, and integrated behavioural-and-pharmacological care delivery are reshaping tobacco use disorder management.
Tobacco use disorder pharmacotherapy has been nicotine replacement, varenicline, and bupropion for years. Cytisine has approval in expanded markets with comparable efficacy to varenicline at lower cost; novel nicotine receptor pharmacotherapy programs are in late-stage trials; integrated behavioural-and-pharmacological care delivery (often through quitlines, primary care, or telehealth) is reshaping how the existing options reach patients. The infrastructure question is the rate-limiting step.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.